Dong-Bing Zhao

Dong-Bing Zhao


Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2011 in World Journal of Gastroenterology
Verified
Journal Article
Open access
XCXu Che
Xu Che
DZDong-Bing Zhao
Dong-Bing Zhao
YWYong-Kai Wu
Yong-Kai Wu
CWCheng-Feng Wang
Cheng-Feng Wang
JCJian-Qiang Cai
Jian-Qiang Cai
PZPing Zhao
Ping Zhao
To present the experience and outcomes of the surgical treatment for the patients with anorectal melanoma from the Cancer Hospital, Chinese Academy of Medical Sciences. Medical records of the diagnosis, surgery, and follow-up of 56 patients with anorectal melanoma who underwent surgery between 1975 and 2008 were retrospectively reviewed. The factors predictive for the survival rate of these patients were identified using multivariate analysis. The 5-year survival rate of the 56 patients with anorectal melanoma was 20%, 36 patients underwent abdominoperineal resection (APR) and 20 patients underwent wide local excision (WLE). The rates of local recurrence of the APR and WLE groups were 16.13% (5/36) and 68.75% (13/20), (P = 0.001), and the median survival time was 22 mo and 21 mo, respectively (P = 0.481). Univariate survival analysis demonstrated that the number of tumor and the depth of invasion had significant effects on the survival (P < 0.05). Multivariate analysis showed that the number of tumor [P = 0.017, 95% confidence interval (CI) = 1.273-11.075] and the depth of invasion (P = 0.015, 95% CI = 1.249-7.591) were independent prognostic factors influencing the survival rate. Complete or R0 resection is the first choice of treatment for anorectal melanoma, prognosis is poor regardless of surgical approach, and early diagnosis is the key to improved survival rate for patients with anorectal melanoma.

1 November 2015 in Journal of Gastrointestinal Surgery
Verified
Journal Article
Closed access
PDF file
CGChun Guang Guo
Chun Guang Guo
DZDong-Bing Zhao
Dong-Bing Zhao
QLQian Liu
Qian Liu
ZZZhi Xiang Zhou
Zhi Xiang Zhou
PZPing Zhao
Ping Zhao
JCJian Qiang Cai
Jian Qiang Cai

14 January 2017 in Oncotarget
Verified
Journal Article
Open access
PDF file
CGChun Guang Guo
Chun Guang Guo
DZDong-Bing Zhao
Dong-Bing Zhao
QLQian Liu
Qian Liu
ZZZhi Xiang Zhou
Zhi Xiang Zhou
PZPing Zhao
Ping Zhao
JCJian Qiang Cai
Jian Qiang Cai
A nomogram to predict lymph node metastasis in patients with early gastric cancer A nomogram to predict lymph node metastasis in patients with early gastric cancer

15 September 2015 in Tumor Biology
Verified
Journal Article
Closed access
PDF file
XBXiaofeng Bai
Xiaofeng Bai
PLPeng Li
Peng Li
YXYibin Xie
Yibin Xie
CGChunguang Guo
Chunguang Guo
YSYuemin Sun
Yuemin Sun
DZDong-Bing Zhao
Dong-Bing Zhao

13 June 2019 in Journal of Oncology
Verified
Journal Article
Open access
PDF file
LZLulu Zhao
Lulu Zhao
HHHuang Huang
Huang Huang
DZDong-Bing Zhao
Dong-Bing Zhao
CWChengfeng Wang
Chengfeng Wang
YTYantao Tian
Yantao Tian
YCYing-Tai Chen
Ying-Tai Chen
Background. The prognostic relevance of gastric tumor location has been reported and debated. Our study was conducted to examine the differences in clinicopathological features, prognostic factors, and overall survival (OS) between patients with proximal gastric cancer (PGC) and distal gastric cancer (DGC).Patients and Methods. Patients with PGC or DGC were identified from the China National Cancer Center Gastric Cancer Database (NCCGCDB) during 1997–2017. Survival analysis was performed via Kaplan-Meier estimates and Cox proportional hazards models.Results. We reviewed 16,119 cases of gastric cancer patients, including 6,479 of PGC and 9,640 of DGC. PGC patients presented as older patients (61.5 versus 56.4 years,P<0.001) and more males (82.9% versus 68.2%,P<0.001). Compared with DGC, PGC was more likely to be in later pT stage (pT3 and pT4, 65.0% versus 52.8%,P<0.001) and lymph node metastasis (54.8% versus 50.9%,P<0.001). In univariate analysis, PGC patients had a worse survival outcome in stage I (Hazard ratio [HR] = 2.04, 95% CI: 1.42-2.94) but a better prognosis in stage IV (HR = 0.85, 95% CI: 0.73-0.98) when compared to DGC patients. However, multivariate analysis demonstrated that PGC was not an independent predictor for poor survival (HR = 1.07, 95% CI: 1.00-1.14). Results from multivariate analysis also revealed that pT4, lymph node metastasis, distant metastasis, no gastrectomy, and Borrmann IV were independent predictors associated with poor survival for both PGC and DGC patients. Additional prognostic factors for PGC patients included underweight (BMI < 18.5) (HR = 1.29, 95% CI: 1.06-1.58), linitis plastica (HR = 2.13, 95% CI: 1.25-3.65), and overweight (23 ≤ BMI <27.5) (HR = 0.80, 95% CI: 0.71-0.90). During the 20-year study period, the 5-year OS increased significantly for both PGC and DGC, with the increase rate of 91.7% and 67.7%, respectively.Conclusion. In China, PGC significantly differed from DGC in clinicopathological characteristics and prognostic factors. However, there was no significant relationship between survival outcome and gastric tumor location.

22 March 2022 in Cancer Medicine
Verified
Journal Article
Open access
PNPenghui Niu
Penghui Niu
HHHuang Huang
Huang Huang
LZLulu Zhao
Lulu Zhao
TWTongbo Wang
Tongbo Wang
XZXiaojie Zhang
Xiaojie Zhang
YCYing-Tai Chen
Ying-Tai Chen
Background: The survival outcomes of younger patients with gastric cancer (GC) have remained controversial. This study explores the clinicopathological characteristics, survival outcomes, and genetic alterations of younger and older patients with GC.Methods: Patients with GC were identified from the China National Cancer Center Gastric Cancer Database (NCCGCDB) during 1998–2018. Survival analysis was conducted using Kaplan–Meier estimates and Cox proportional hazards models. Sequencing datasets were enrolled from The Cancer Genome Atlas (TCGA) and Memorial Sloan–Kettering Cancer Center (MSKCC) databases.Results: A total of 1146 younger (<40 years of age) and 16,988 older (≥40 years of age) cases were included in the study. Younger patients had more poorly differentiated lesions than older patients (53.7% vs. 33.8%, respectively; p < 0.0001), and were more often pTNM stage IV (19.5% vs. 11.8%, respectively; p < 0.001). The 5‐year overall survival (OS) of patients from the NCCGCDB increased from 1998 to 2018. Younger patients with pTNM stage III had a lower survival rate than older patients (p = 0.014), while no differences by age were observed at other stages. The mutation frequency of the LRP1B, GNAS, APC, and KMT2D genes was higher for older than younger patients (p < 0.05 for all genes). While not significantly different, younger patients from the TCGA and MSKCC databases were more likely to have CDH1, RHOA, and CTNNB1 gene mutations.Conclusions: A stable proportion and improved survival of younger patients were reported using NCCGCDB data. Younger patients with pTNM stage III had lower rates of survival than older patients. Distinct molecular characteristics were identified in younger GC patients which may partly explain the histopathology and prognosis specific to this subpopulation.